Tirofiban Versus Alteplase for Patients With Minor Acute Ischemic Stroke: A Target Trial Emulation Study

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• Acute ischemic stroke presents a significant health challenge.
• Tirofiban is being investigated as a potential therapeutic agent.
• Early intervention within 4.5 hours of symptom onset is critical for minor stroke patients.

Purpose of the Study:

• To evaluate the efficacy and safety of tirofiban in patients with minor acute ischemic stroke.
• To compare functional outcomes and safety profiles of tirofiban versus alteplase.
• To assess tirofiban's impact on neurological deterioration and bleeding events.

Main Methods:

• A target trial emulation using observational data.
• Inclusion criteria: minor stroke (NIHSS ≤5) treated within 4.5 hours.
• Primary outcome: excellent functional outcome (mRS 0-1) at 90 days; secondary outcomes included safety and neurological status.

Main Results:

• No significant difference in 90-day excellent functional outcome (mRS 0-1) between tirofiban and alteplase groups.
• Tirofiban was associated with significantly lower risks of 24-hour neurological deterioration (RR 0.31).
• Tirofiban demonstrated reduced risks of intracranial hemorrhage (RR 0.06) and any bleeding (RR 0.13) with no symptomatic intracranial hemorrhage.

Conclusions:

• Intravenous tirofiban is a potential treatment option for minor acute ischemic stroke within 4.5 hours.
• Tirofiban offers comparable functional outcomes to alteplase with improved safety regarding bleeding and neurological deterioration.
• Further randomized trials are warranted to confirm these findings and establish tirofiban's role in stroke management.